Data / Drug companies / Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries, Inc.: 24 products in the FDA NDC directory, labeler code 70095
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sun Pharmaceutical Industries, Inc. (labeler code 70095) lists 24 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 20 prescription drugs, 4 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 31, 2026.
The request: Watch Sun Pharmaceutical Industries, Inc. (FDA labeler code 70095): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70095
- Products in commercial distribution
- 24
- Packages
- 31
- Finished drugs by generic name
- 12
- Prescription products
- 20
- Over the counter products
- 0
- Flagged as original packager
- 11 of 11 products that carry the flag
- Started marketing in the last 12 months
- 12
- Earliest marketing start
- March 27, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 18 | 75% |
| Bulk ingredients | 4 | 16.7% |
| Biologics (BLA) | 1 | 4.2% |
| Authorized generics (NDA) | 1 | 4.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 20 | 83.3% |
| Bulk ingredients | 4 | 16.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Pomalidomide | 4 | 12 |
| Deflazacort | 4 | 11 |
| Desmopressin acetate | 2 | 27 |
| Bisoprolol fumarate | 2 | 25 |
| Pantoprazole sodium | 1 | 54 |
| Cosibelimab | 1 | 1 |
| Progesterone | 1 | 39 |
| Tofacitinib | 1 | 23 |
| Sodium bicarbonate | 1 | 51 |
| Eribulin mesylate | 1 | 17 |
| Phytonadione | 1 | 31 |
| Azithromycin monohydrate | 1 | 7 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 4 | 16.7% |
| Injection, solution | 4 | 16.7% |
| Tablet | 4 | 16.7% |
| Powder | 4 | 16.7% |
| Injection, powder, lyophilized, for solution | 2 | 8.3% |
| Tablet, film coated | 2 | 8.3% |
| Insert | 1 | 4.2% |
| Solution | 1 | 4.2% |
| Injection | 1 | 4.2% |
| Injection, emulsion | 1 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pomalidomide | 70095-060 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Pomalidomide | 70095-059 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Pomalidomide | 70095-058 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Pomalidomide | 70095-057 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Methylnaltrexone bromide | 70095-218 | Powder | Bulk ingredients | June 10, 2026 |
| Phytonadione | 70095-154 | Injection, emulsion | Generic drugs (ANDA) | June 10, 2026 |
| Tofacitinib | 70095-008 | Solution | Generic drugs (ANDA) | June 3, 2026 |
| Istradefylline | 70095-214 | Powder | Bulk ingredients | May 25, 2026 |
| Vismodegib | 70095-210 | Powder | Bulk ingredients | May 25, 2026 |
| Progesterone | 70095-136 | Insert | Authorized generics (NDA) | April 27, 2026 |
| Sincalide | 70095-212 | Powder | Bulk ingredients | April 16, 2026 |
| Unloxcyt | 70095-130 | Injection, solution | Biologics (BLA) | December 8, 2025 |
| Eribulin mesylate | 70095-080 | Injection | Generic drugs (ANDA) | May 15, 2025 |
| Deflazacort | 70095-043 | Tablet | Generic drugs (ANDA) | March 19, 2025 |
| Deflazacort | 70095-042 | Tablet | Generic drugs (ANDA) | March 19, 2025 |
| Deflazacort | 70095-041 | Tablet | Generic drugs (ANDA) | March 19, 2025 |
| Deflazacort | 70095-040 | Tablet | Generic drugs (ANDA) | March 19, 2025 |
| Sodium bicarbonate | 70095-050 | Injection, solution | Generic drugs (ANDA) | March 15, 2024 |
| Bisoprolol fumarate | 70095-020 | Tablet, film coated | Generic drugs (ANDA) | March 10, 2024 |
| Bisoprolol fumarate | 70095-019 | Tablet, film coated | Generic drugs (ANDA) | March 10, 2024 |
| Desmopressin Acetate | 70095-031 | Injection, solution | Generic drugs (ANDA) | June 20, 2023 |
| Desmopressin Acetate | 70095-026 | Injection, solution | Generic drugs (ANDA) | April 3, 2023 |
| Pantoprazole sodium | 70095-024 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 3, 2023 |
| Azithromycin monohydrate | 70095-025 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 27, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.